Improved anticoagulant effect of fucosylated chondroitin sulfate orally administered as gastroresistant tablets

Summary

Fucosylated chondroitin sulfate (FucCS) is a potent anticoagulant polysaccharide extracted from sea cucumber. Its anticoagulant activity is attributed to the presence of unique branches of sulfated fucose. Although this glycosaminoglycan exerts an antithrombotic effect following oral administration, high doses are necessary to achieve the maximum effect. The diminished activity of FucCS following oral administration is likely due to its degradation in the gastrointestinal tract and its limited ability to cross the intestinal cell membranes. The latter aspect is particularly difficult to overcome. However, gastroresistant tablet formulation may help limit the degradation of FucCS in the gastrointestinal tract. In the present work, we found that the oral administration of FucCS as gastroresistant tablets produces a more potent and prolonged anticoagulant effect compared with its administration as an aqueous solution, with no significant changes in the bleeding tendency or arterial blood pressure. Experiments using animal models of arterial thrombosis initiated by endothelial injury demonstrated that FucCS delivered as gastro-protective tablets produced a potent antithrombotic effect, whereas its aqueous solution was ineffective. However, there was no significant difference between the effects of FucCS delivered as gastroresistant tablets or as aqueous solution in a venous thrombosis model, likely due to the high dose of thromboplastin used. New oral anticoagulants tested in these experimental models for comparison showed significantly increased bleeding tendencies. Our study provides a framework for developing effective oral anticoagulants based on sulfated polysaccharides from marine organisms. The present results suggest that FucCS is a promising oral anticoagulant.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

Glycosaminoglycans - oral anticoagulants - antithrombotic drugs - oral delivery anticoagulant - drug development

• References

• 1 Mourão PAS.. Perspective on the use of sulfated polysaccharides from marine organisms as a source of new antithrombotic drugs. Mar Drugs 2015; 13: 2770-2784
• 2 Pomin VH, Mourão PAS.. Structure, biology, evolution and medical importance of sulfated -fucans and -galactans. Glycobiology 2008; 18: 1016-1027
• 3 Pavão MS.. Glycosaminoglycans analogs from marine invertebrates: structure, biological effects, and potential as new therapeutics. Front Cell Infect Microbiol 2014; 4: 123
• 4 Glauser BF, Mourão PAS, Pomin VH.. Marine sulfated glycans with serpin-unrelated anticoagulant properties. Adv Clin Chem 2013; 62: 269-303
• 5 Quinderé AL, Santos GR, Oliveira SN. et al. Is the antithrombotic effect of sulfated galactans independent of serpin? J Thromb Haemost . 2014; 12: 43-53
• 6 Fonseca RJ, Mourão PAS.. Fucosylated chondroitin sulfate as a new antithrombotic agent. Thromb Haemost 2006; 96: 822-829
• 7 Mourão PAS, Guimarães B, Mulloy B. et al. Antithrombotic activity of a fucosylated chondroitin sulfate from echinoderm: Sulfated fucose branches on the polysaccharide account for its antithrombotic action. Br J Haematol 1998; 101: 647-652
• 8 Hu S, Chang Y, He M. et al. Fucosylated chondroitin sulfate from sea cucumber improves insulin sensitivity via activation of PI3K/PKB pathway. J Food Sci 2014; 79: 1424-1429
• 9 Hu S, Tian YY, Chang YG. et al. Fucosylated chondroitin sulfate from sea cucumber improves glucose metabolism and activates insulin signalling in the liver of insulin-resistant mice. J Med Food 2014; 17: 749-757
• 10 Glauser BF, Pereira MS, Monteiro RQ. et al. Serpin-independent anticoagulant activity of a fucosylated chondroitin sulfate. Thromb Haemost 2008; 100: 420-428
• 11 Pacheco RG, Vicente CP, Zancan P. et al. Different antithrombotic mechanisms among glycosaminoglycans revealed with a new fucosylated chondroitin sulfate from an echinoderm. Blood Coag Fibrin 2000; 11: 563-573
• 12 Zancan P, Mourão PAS.. Venous and arterial thrombosis in rat models: dissociation of the antithrombotic effects of glycosaminoglycans. Blood Coag Fibrin 2004; 15: 45-54
• 13 Wessler S, Reimer SM, Sheps MC.. Biological assay of a thrombosis inducing activity in human serum. J Appl Physiol 1959; 14: 943-946
• 14 Eitzman DT, Westrick RJ, Nabel EG. et al. Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice. Blood 2000; 95: 577-580
• 15 Herbert JM, Bernat A, Maffrand JP.. Importance of platelets in experimental venous thrombosis in rats. Blood 1992; 80: 2281-2286
• 16 Fonseca RJ, Oliveira SN, Pomin VH. et al. Effects of oversulfated and fucosylated chondroitin sulfates on coagulation. Challenges for the study of anticoagulant polysaccharides. Thromb Haemost 2010; 103: 994-1004
• 17 Fonseca RJ, Santos GR, Mourão PAS.. Effects of polysaccharides enriched in 2, 4-disulfated fucose units on coagulation, thrombosis and bleeding. Practical and conceptual implications Thromb Haemost 2009; 102: 829-836
• 18 Santos GR, Glauser BF, Parreiras LA. et al. Distinct structures of the α-fucose branches in fucosylated chondroitin sulfates do not affect their anticoagulant activity. Glycobiology 2015; 25: 1043-1052
• 19 Mourão PAS, Pereira MS, Pavão MS. et al. Structure and anticoagulant activity of a fucosylated chondroitin sulfate from echinoderm. Sulfated fucose branches on the polysaccharide account for its high anticoagulant action. J Biol Chem 1996; 271: 23973-23984
• 20 Rocha HAO, Moraes FA, Trindade ES. et al. Structural and hemostatic activities of a sulfated galactofucan from the brown alga Spatoglossum schroederi: an ideal antithrombotic agent? J Biol Chem . 2006; 280: 41278-41288
• 21 Wang Y, Nie M, Lu Y. et al. Fucoidan exerts protective effects against diabetic nephropathy related to spontaneous diabetes through the NF-kB signalling pathway in vivo and in vitro. Int J Mol Med 2015; 35: 1067-1073
• 22 Azuma K, Ishihara T, Nakamoto H. et al. Effects of oral administration of fucoidan extracted from Cladosiphon okamuranus on tumor growth and survival time in a tumor-bearing mouse model. Mar Drugs 2012; 10: 2337-2348
• 23 Hernández-Corona DM, Martínez-Abundis E, González-Ortiz M.. Effect of fucoidan administration on insulin secretion and insulin resistance in overweight or obese adults. J Med Food 2014; 17: 830-832
• 24 Hu M, Hsi-Hsien L, Weng-Ching K.. Hypolipidemic Effect of glycosaminoglycans from the sea cucumber Metriatyla scabra in rats fed a cholesterol-supplemented diet. J Agric Food Chem 2002; 50: 3602-3606
• 25 Ronca G, Ronca F, Palmieri L.. Anti-inflammatory activity of chondroitin sulfate. Osteoarthrits Cart 1998; 6: 14-21
• 26 Volpi N.. Oral bioavailability of chondroitin sulfate (Condrosulf ®) and its constituents in healthy male volunteers. Osteoarthrits Cart 2002; 10: 768-777
• 27 Houin G, Barthe L, Woodley J. et al. In vitro intestinal degradation and absorption of chondroitin sulfate, a glycosaminoglycan drug. Arzneimittelforshung 2004; 54: 286-292
• 28 Gomez-Orellana I, Goldberg M.. Challenges for the oral delivery of macromolecules. Nat Rev 2003; 2: 289-295
• 29 Hwang SR, Byun Y.. Advances in oral macromolecular drug delivery. Expert Opin Drug Deliv 2014; 11: 1955-1967
• 30 Leadley Jr RJ, Chi L, Rebello SS. et al. Contribution of in vivo models of thrombosis to the discovery and development of novel antithrombotic agents. J Pharmacol Toxicol Methods 2000; 43: 101-116
• 31 Lauer A, Pfeilschifter W, Schaffer CB. et al. Intracerebral haemorrhage associated with antithrombotic treatment: translational insights from experimental studies. Lancet Neurol 2013; 12: 394-405
• 32 McMahon BJ, Kwaan HC.. The new or non-vitamin K antagonist oral anticoagulants: what have we learned since their debut. Semin Thromb Hemost 2015; 41: 188-194
• 33 Grass GM, Sinko PJ.. Physiologically-based pharmacokinetic simulation modelling. Adv Drug Deliv Rev 2002; 54: 433-451